Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alamin SN Injection is a sterile, non-pyrogenic, nutritional amino acid infusion developed and manufactured by Albert David. It is a 10% amino acid solution designed for parenteral nutrition to provide a balanced profile of essential and non-essential amino acids to patients who cannot receive adequate oral or enteral nutrition. The formulation typically includes 15 amino acids: L-Isoleucine, L-Leucine, L-Lysine, L-Methionine, L-Phenylalanine, L-Threonine, L-Tryptophan, L-Valine, L-Arginine, L-Histidine, Glycine, L-Alanine, L-Proline, L-Serine, and L-Tyrosine. It is indicated for the prevention and treatment of nitrogen loss or for maintaining negative nitrogen balance in conditions such as post-operative recovery, severe trauma, or gastrointestinal disorders where the digestive tract is non-functional or inaccessible.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Alamin SN Injection.